Total Payments
$97,613
2024 Payments
$1,837
Companies
41
Transactions
519
Medicare Patients
9,433
Medicare Billing
$545,530
Payment Breakdown by Category
Other$75,970 (77.8%)
Food & Beverage$16,585 (17.0%)
Travel$4,414 (4.5%)
Consulting$333.00 (0.3%)
Education$310.40 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $75,970 | 33 | 77.8% |
| Food and Beverage | $16,585 | 466 | 17.0% |
| Travel and Lodging | $4,414 | 12 | 4.5% |
| Consulting Fee | $333.00 | 1 | 0.3% |
| Education | $310.40 | 7 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $78,375 | 147 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $4,731 | 18 | $0 (2024) |
| Abbott Laboratories | $3,588 | 35 | $0 (2024) |
| Amgen Inc. | $2,629 | 49 | $0 (2024) |
| CVRx, Inc. | $1,121 | 7 | $0 (2023) |
| ABIOMED | $894.35 | 15 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $759.07 | 43 | $0 (2024) |
| Medtronic Vascular, Inc. | $527.72 | 3 | $0 (2020) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $508.30 | 19 | $0 (2024) |
| PFIZER INC. | $497.28 | 31 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,837 | 74 | Novartis Pharmaceuticals Corporation ($427.41) |
| 2023 | $1,438 | 66 | Novartis Pharmaceuticals Corporation ($274.66) |
| 2022 | $1,804 | 92 | Novartis Pharmaceuticals Corporation ($370.18) |
| 2021 | $3,550 | 50 | AstraZeneca Pharmaceuticals LP ($2,264) |
| 2020 | $3,666 | 28 | AstraZeneca Pharmaceuticals LP ($2,370) |
| 2019 | $12,708 | 18 | Novartis Pharmaceuticals Corporation ($11,723) |
| 2018 | $22,254 | 69 | Novartis Pharmaceuticals Corporation ($20,193) |
| 2017 | $50,356 | 122 | Novartis Pharmaceuticals Corporation ($45,276) |
All Payment Transactions
519 individual payment records from CMS Open Payments — Page 1 of 21
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $21.17 | General |
| Category: Cardiovascular | ||||||
| 12/10/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $21.34 | General |
| Category: DIABETES | ||||||
| 12/09/2024 | Philips North America LLC | (5091) Amb Mon & Diag Und (Device) | Food and Beverage | Cash or cash equivalent | $22.10 | General |
| Category: Medical Device | ||||||
| 12/05/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $19.88 | General |
| Category: Obesity | ||||||
| 11/25/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $18.51 | General |
| Category: Cardiovascular | ||||||
| 11/22/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $15.48 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 11/12/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $13.82 | General |
| Category: Cardiology | ||||||
| 10/31/2024 | Biosense Webster, Inc. | CARTO 3 (Device), NUVISION ICE CATHETER, OCTARAY MAPPING CATHETER | Food and Beverage | In-kind items and services | $39.58 | General |
| Category: Cardiology | ||||||
| 10/29/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $21.50 | General |
| Category: DIABETES | ||||||
| 10/21/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug), LEQVIO | Food and Beverage | In-kind items and services | $22.42 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $18.18 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 10/16/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $16.35 | General |
| Category: Cardiology | ||||||
| 10/15/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $20.97 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 10/03/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $12.51 | General |
| Category: Cardiovascular | ||||||
| 10/01/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $28.04 | General |
| Category: Not Applicable | ||||||
| 09/30/2024 | Baxter Healthcare | Hillrom - Carnation Ambulatory Monitor (Device) | Food and Beverage | In-kind items and services | $17.61 | General |
| Category: Cardiac Arrhythmia Monitoring | ||||||
| 09/27/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $22.51 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 09/26/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $23.89 | General |
| Category: Obesity | ||||||
| 09/25/2024 | Abbott Laboratories | 2ND GEN CENTRIMAG PRIMARY CONSOLE (Device) | Food and Beverage | In-kind items and services | $23.80 | General |
| Category: Heart Failure | ||||||
| 09/24/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $16.26 | General |
| Category: Cardiovascular | ||||||
| 09/19/2024 | ATRICURE, INC. | ATRICLIP LAA EXCLUSION SYSTEM (Device) | Food and Beverage | In-kind items and services | $25.71 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/06/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $24.62 | General |
| Category: DIABETES | ||||||
| 09/05/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.84 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/26/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug), ENTRESTO | Food and Beverage | In-kind items and services | $16.25 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/23/2024 | Kiniksa Pharmaceuticals International, plc | Arcalyst (Drug) | Food and Beverage | In-kind items and services | $27.37 | General |
| Category: Not Applicable | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 21 | 2,081 | 2,608 | $356,671 | $134,213 |
| 2022 | 15 | 2,208 | 2,945 | $375,715 | $139,603 |
| 2021 | 16 | 2,713 | 3,722 | $427,558 | $159,161 |
| 2020 | 15 | 2,431 | 3,393 | $319,541 | $112,553 |
Total Patients
9,433
Total Services
12,668
Medicare Billing
$545,530
Procedure Codes
75
All Medicare Procedures & Services
75 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 198 | 361 | $101,802 | $48,347 | 47.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 83 | 215 | $43,645 | $20,386 | 46.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 100 | 120 | $25,200 | $10,209 | 40.5% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 161 | 162 | $33,534 | $8,762 | 26.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 62 | 64 | $25,344 | $8,645 | 34.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 47 | 47 | $18,988 | $8,214 | 43.3% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 116 | 118 | $24,426 | $6,462 | 26.5% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 798 | 992 | $26,784 | $6,444 | 24.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 42 | 42 | $13,650 | $5,340 | 39.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 23 | 23 | $6,210 | $2,217 | 35.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 24 | 32 | $4,544 | $1,894 | 41.7% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Facility | 2023 | 24 | 24 | $5,688 | $1,465 | 25.8% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 131 | 135 | $8,370 | $1,455 | 17.4% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Office | 2023 | 92 | 93 | $4,371 | $1,016 | 23.3% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 16 | 16 | $3,792 | $976.96 | 25.8% |
| 93307 | Ultrasound of heart | Facility | 2023 | 12 | 12 | $1,752 | $418.92 | 23.9% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2023 | 36 | 36 | $1,692 | $393.41 | 23.3% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2023 | 22 | 22 | $1,562 | $371.36 | 23.8% |
| 93244 | Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 14 | 14 | $994.00 | $263.48 | 26.5% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Office | 2023 | 15 | 15 | $1,065 | $253.20 | 23.8% |
| 93248 | Heart rhythm review and interpretation of continous external ekg over 8-15 days | Office | 2023 | 12 | 12 | $936.00 | $248.64 | 26.6% |
| 93308 | Ultrasound of heart, follow-up | Facility | 2023 | 11 | 11 | $1,075 | $198.90 | 18.5% |
| 93242 | Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 12 | 12 | $540.00 | $117.72 | 21.8% |
| 93321 | Ultrasound of heart blood flow, valves and chambers, follow-up | Facility | 2023 | 15 | 15 | $427.00 | $80.22 | 18.8% |
| 93325 | Ultrasound of heart with color-depicted blood flow, rate and valve function | Facility | 2023 | 15 | 15 | $280.00 | $34.30 | 12.2% |
About Dr. Shadi Daoud, M.D
Dr. Shadi Daoud, M.D is a Internal Medicine healthcare provider based in Las Vegas, Nevada. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1699739151.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Shadi Daoud, M.D has received a total of $97,613 in payments from pharmaceutical and medical device companies, with $1,837 received in 2024. These payments were reported across 519 transactions from 41 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($75,970).
As a Medicare-enrolled provider, Daoud has provided services to 9,433 Medicare beneficiaries, totaling 12,668 services with total Medicare billing of $545,530. Data is available for 4 years (2020–2023), covering 75 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Advanced Heart Failure and Transplant Cardiology, Cardiovascular Disease
- Location Las Vegas, NV
- Active Since 04/13/2006
- Last Updated 01/25/2022
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1699739151
Products in Payments
- ENTRESTO (Drug) $77,673
- FARXIGA (Drug) $4,537
- Repatha (Biological) $2,449
- Barostim Neo System (Device) $1,121
- CardioMEMS HF System (Device) $1,044
- Impella (Device) $894.35
- LEQVIO (Drug) $701.86
- ELIQUIS (Drug) $627.48
- JARDIANCE (Drug) $508.30
- XARELTO (Drug) $493.02
- LifeVest (Device) $383.35
- Ensite Cardiac Mapping System (Device) $352.15
- Confirm Rx (Device) $345.22
- CAMZYOS (Drug) $314.66
- Advisor Catheter (Device) $312.94
- Pacemakers (Device) $312.32
- VERQUVO (Drug) $220.12
- Ozempic (Drug) $215.42
- (5044) MCOT (Device) $204.23
- Corlanor (Drug) $180.04
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Las Vegas
Fadi Braiteh, M.d, M.D
Internal Medicine — Payments: $4.0M
Internal Medicine $4.0M
Samer Nakhle, Md, MD
Internal Medicine — Payments: $911,236
Internal Medicine $911,236
Maxine Ingham, Md, MD
Internal Medicine — Payments: $602,393
Internal Medicine $602,393
Richard Cottiero, Md, MD
Internal Medicine — Payments: $289,614
Internal Medicine $289,614
Dr. Michael Jacobs, M.d., Ph.d, M.D., PH.D
Internal Medicine — Payments: $237,373
Internal Medicine $237,373
Dr. Kevin Dunsmoor, Do, DO
Internal Medicine — Payments: $197,836
Internal Medicine $197,836